$0.04▴ 19.20%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-29.9%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
OneMedNet Corp's earnings-quality signal is not available yet. Revenue is contracting year over year. Very low debt relative to its asset base.
Key numbers
Recent news
Sentiment · last 30 days29 articles
18 bullish11 neutral0 bearish
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.